Sangamo Therapeutics, Inc.

LSE:0R1D Stock Report

Market Cap: US$448.5m

Sangamo Therapeutics Valuation

Is 0R1D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R1D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R1D ($2.01) is trading below our estimate of fair value ($106.98)

Significantly Below Fair Value: 0R1D is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R1D?

Key metric: As 0R1D is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0R1D. This is calculated by dividing 0R1D's market cap by their current revenue.
What is 0R1D's PS Ratio?
PS Ratio8.2x
SalesUS$52.29m
Market CapUS$448.53m

Price to Sales Ratio vs Peers

How does 0R1D's PS Ratio compare to its peers?

The above table shows the PS ratio for 0R1D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
OXB Oxford Biomedica
4.4x21.0%UK£430.9m
BVXP Bioventix
14.7xn/aUK£199.7m
GNS Genus
1.7x3.5%UK£1.1b
AVCT Avacta Group
7.6x14.3%UK£172.0m
0R1D Sangamo Therapeutics
8.2x41.8%US$448.5m

Price-To-Sales vs Peers: 0R1D is expensive based on its Price-To-Sales Ratio (8.2x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does 0R1D's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.42b
OXB Oxford Biomedica
4.4x21.0%US$543.25m
TRX Tissue Regenix Group
1.7x15.1%US$54.78m
VRCI Verici Dx
2.1x78.8%US$9.17m
0R1D 8.2xIndustry Avg. 7.9xNo. of Companies8PS020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0R1D is expensive based on its Price-To-Sales Ratio (8.2x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is 0R1D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R1D PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.2x
Fair PS Ratio9.5x

Price-To-Sales vs Fair Ratio: 0R1D is good value based on its Price-To-Sales Ratio (8.2x) compared to the estimated Fair Price-To-Sales Ratio (9.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R1D forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.01
US$5.80
+188.6%
63.0%US$10.00US$1.00n/a5
Nov ’25US$1.91
US$3.80
+99.0%
65.3%US$8.00US$1.00n/a5
Oct ’25US$0.84
US$3.80
+354.5%
65.3%US$8.00US$1.00n/a5
Sep ’25US$0.84
US$3.80
+353.7%
65.3%US$8.00US$1.00n/a5
Aug ’25US$0.74
US$3.80
+416.0%
65.3%US$8.00US$1.00n/a5
Jul ’25US$0.34
US$3.50
+919.8%
67.5%US$8.00US$1.00n/a6
Jun ’25US$0.57
US$3.50
+517.5%
67.5%US$8.00US$1.00n/a6
May ’25US$0.55
US$3.50
+538.0%
67.5%US$8.00US$1.00n/a6
Apr ’25US$0.64
US$3.50
+444.6%
67.5%US$8.00US$1.00n/a6
Mar ’25US$1.10
US$3.17
+187.9%
71.6%US$8.00US$1.00n/a6
Feb ’25US$0.48
US$3.17
+557.1%
71.6%US$8.00US$1.00n/a6
Jan ’25US$0.55
US$3.17
+472.3%
71.6%US$8.00US$1.00n/a6
Dec ’24US$0.45
US$3.17
+597.4%
71.6%US$8.00US$1.00n/a6
Nov ’24US$0.55
US$6.58
+1,089.6%
33.2%US$10.00US$3.60US$1.918
Oct ’24US$0.60
US$6.01
+898.9%
43.3%US$10.00US$1.50US$0.849
Sep ’24US$0.99
US$6.01
+507.9%
43.3%US$10.00US$1.50US$0.849
Aug ’24US$1.29
US$7.38
+472.6%
54.7%US$16.00US$1.50US$0.749
Jul ’24US$1.30
US$7.38
+469.7%
54.7%US$16.00US$1.50US$0.349
Jun ’24US$1.13
US$7.38
+553.8%
54.7%US$16.00US$1.50US$0.579
May ’24US$1.47
US$8.38
+470.5%
58.2%US$16.00US$1.50US$0.559
Apr ’24US$1.75
US$11.28
+543.7%
39.2%US$16.00US$4.20US$0.648
Mar ’24US$2.93
US$12.36
+321.9%
48.3%US$25.00US$4.20US$1.109
Feb ’24US$3.59
US$12.78
+255.9%
56.0%US$25.00US$4.00US$0.489
Jan ’24US$3.01
US$13.67
+354.8%
52.5%US$25.00US$4.00US$0.559
Dec ’23US$3.66
US$13.67
+273.4%
52.5%US$25.00US$4.00US$0.459
Nov ’23US$4.47
US$14.33
+220.7%
49.9%US$25.00US$5.00US$0.559

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€826.3m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€45.30

7D

-6.3%

1Y

-26.8%

hVIVO

UK£182.0m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.26

7D

-3.8%

1Y

43.8%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.00

7D

-2.9%

1Y

19.9%